Nexalin Technology (NXL) Other Non-Current Assets (2024 - 2026)
Nexalin Technology (NXL) posted Other Non-Current Assets of $40000.0 for Q2 2026, up 4529.63% on a QoQ basis from $864.0 in Q4 2024.
Powered by 
Analysis
Nexalin Technology (NXL) Other Non-Current Assets (2024 - 2026) Analysis & Trends
Nexalin Technology has reported Other Non-Current Assets for 2 years, with the latest figure at $40000.0 in Q2 2026.
- On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $40000.0 in Q2 2026; TTM through Jun 2026 was $40000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $864.0, changed N/A from the prior year.
- Other Non-Current Assets was $40000.0 for Q2 2026 at Nexalin Technology, up from $864.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $54414.0 in Q2 2024, with the low at $864.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 4.32 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 3.23 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 45.22 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 616.40 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 434.00 Mn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 273.70 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 215.10 Mn |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | 40,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40,000.00 |
| Dec 31, 2024 | 864.00 |
| Jun 30, 2024 | 54,414.00 |